Common use of Biosimilar Competition Clause in Contracts

Biosimilar Competition. During the portion of the applicable Royalty Term in a particular country where there are one or more products being sold in such country that are Biosimilar Products with respect to such Product, then the Base Royalty Rates set forth in Section 8.5(b), as adjusted by Section 8.5(c)(ii), with respect to such Product shall be reduced as follows:

Biosimilar Competition. During the portion of the applicable Royalty Term in a particular country where there are one or more products being sold in such country that are Biosimilar Products with respect to such Product, then the Base Royalty Rates set forth in Section 8.5(b8.4(b), as adjusted by Section 8.5(c)(ii8.4(c)(ii), with respect to such Product shall be reduced as follows:

Biosimilar Competition. During the portion of the applicable Royalty Term in a particular country where there are one or more products being sold in such country that are Biosimilar Products with respect to such Product, then the Base Royalty Rates set forth in Section 8.5(b8.3(b), as adjusted by Section 8.5(c)(ii8.3(c)(ii), with respect to such Product shall be reduced as follows:

Biosimilar Competition. During the portion of the applicable Royalty Term in a particular country where there are one or more products being sold in such country that are Biosimilar ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Products with respect to such Product, then the Base Royalty Rates set forth in Section 8.5(b8.4(b), as adjusted by Section 8.5(c)(ii8.4(c)(ii), with respect to such Product shall be reduced as follows:

Biosimilar Competition. During If, during the portion of the applicable Royalty Term for a Licensed Product in a particular country where there are country, one or more products being Biosimilars is sold in such country that are Biosimilar Products with respect to such Productcountry, then the Base Royalty Rates applicable royalty rates set forth in Section 8.5(b), as adjusted by Section 8.5(c)(ii), with respect to 6.6(a) for such Licensed Product in such country shall be reduced in such country by [***] commencing at such time that the market penetration of the Biosimilars in such country is equal to or greater than [***], as follows:determined by dividing (i) [***] by (ii) [***].